IDO5L
Based on 3 publication(s) in Google Scholar
IDO5L is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 67 nM.
For research use only. We do not sell to patients.
- Purity: 99.65%
- CAS No.: 914471-09-3
- Formula: C9H7ClFN5O2
- Molecular Weight:271.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Human Metabolite Library
HY-L123
-
Metabolic Enzyme Compound Library
HY-L146
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) IDO5L
More
Biological Activity
|
IDO 67 nM (IC50) |
IDO 19 nM (IC50, in HeLa cell) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
14.88 μM
Compound: IDO5L
|
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 38754563] |
| B16 | IC50 |
1 μM
Compound: 5l
|
Inhibition of indoleamine 2,3-dioxygenase in mouse B16 cells assessed as kynurenine formation by adjusted cell-based spectrophotometry
Inhibition of indoleamine 2,3-dioxygenase in mouse B16 cells assessed as kynurenine formation by adjusted cell-based spectrophotometry
|
[PMID: 19507862] |
| B16 | IC50 |
46 nM
Compound: 5l
|
Inhibition of indoleamine 2,3-dioxygenase in mouse B16 cells assessed as kynurenine formation by spectrophotometry
Inhibition of indoleamine 2,3-dioxygenase in mouse B16 cells assessed as kynurenine formation by spectrophotometry
|
[PMID: 19507862] |
| HeLa | EC50 |
19 nM
Compound: 78
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability
|
[PMID: 33569941] |
| HeLa | IC50 |
0.058 μM
Compound: Incyte-5l
|
Inhibition of IDO1 in IFN-gamma-stimulated human HeLa cells assessed as decrease in kynurenine levels after 48 hrs
Inhibition of IDO1 in IFN-gamma-stimulated human HeLa cells assessed as decrease in kynurenine levels after 48 hrs
|
[PMID: 31525930] |
| HeLa | IC50 |
19 nM
Compound: 2
|
Inhibition of IDO1 in IFN-gamma-stimulated human HeLa cells assessed as decrease in kynurenine levels after 48 hrs
Inhibition of IDO1 in IFN-gamma-stimulated human HeLa cells assessed as decrease in kynurenine levels after 48 hrs
|
[PMID: 28523098] |
| HeLa | IC50 |
19 nM
Compound: 5l
|
Inhibition of indoleamine 2,3-dioxygenase in IFN-gamma-stimulated human HeLa cells assessed as kynurenine formation by spectrophotometry
Inhibition of indoleamine 2,3-dioxygenase in IFN-gamma-stimulated human HeLa cells assessed as kynurenine formation by spectrophotometry
|
[PMID: 19507862] |
| HK-2 | IC50 |
30.81 μM
Compound: IDO5L
|
Cytotoxicity against HK-2 cells
Cytotoxicity against HK-2 cells
|
[PMID: 38754563] |
| MDA-MB-231 | EC50 |
59 nM
Compound: 5l
|
Inhibition of IDO1 in IFNgamma-induced human MDA-MB-231 cells using tryptophan as substrate preincubated for 4 hrs followed by substrate addition for 5 hrs by spectrophotometric method
Inhibition of IDO1 in IFNgamma-induced human MDA-MB-231 cells using tryptophan as substrate preincubated for 4 hrs followed by substrate addition for 5 hrs by spectrophotometric method
|
[PMID: 27994758] |
| P815 | IC50 |
0.1 μM
Compound: 5l
|
Inhibition of mouse IDO1 in P815 clone 6 cells by HPLC analysis
Inhibition of mouse IDO1 in P815 clone 6 cells by HPLC analysis
|
[PMID: 22616902] |
| P815 | IC50 |
60 μM
Compound: 5l
|
Inhibition of mouse TDO in P815 clone 12 cells by HPLC analysis
Inhibition of mouse TDO in P815 clone 12 cells by HPLC analysis
|
[PMID: 22616902] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 914471-09-3
-
Appearance Solid
-
Molecular Weight 271.64
-
Formula C9H7ClFN5O2
-
Color Off-white to yellow
-
SMILES
ON/C(C1=NON=C1N)=N/C2=CC=C(F)C(Cl)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Chem Sci
A tumor acidity activatable and Ca2+-assisted immuno-nanoagent enhances breast cancer therapy and suppresses cancer recurrence. [Abstract]2020 Jun 29;11(28):7429-7437. PMID: 34123024 -
Pharmaceuticals (Basel)
Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2. [Abstract]2022 Aug 31;15(9):1090. PMID: 36145311 -
Chem Commun (Camb)
Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer. [Abstract]2020 Jan 30;56(9):1389-1392. PMID: 31912821
Solvent & Solubility
DMSO : ≥ 52 mg/mL (191.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice[1]
A single subcutaneous 100 mg/kg dose of IDO5L is administered to naive C57BL/6 mice bearing GM-CSF-secreting B16 tumors. Blood is harvested from individual mice over 8 h. Kynurenine and IDO5L concentrations are measured by LCMS. Reductions of kynurenine levels by 50-60% are observed between 2 and 4 h, with maximum inhibition seen at 2.5 h. Tumors are allowed to grow until day 7 when 14 days of subcutaneous dosing of IDO5L at 25, 50, and 75 mg/kg b.i.d. is initiated. Dose dependent inhibition of tumor growth is correlated with increasing exposures of IDO5L in plasma.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yue EW, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem. 2009 Dec 10;52(23):7364-7. [Content Brief]
[2]. Huang X, et al. Synthesis of [(18) F] 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression. J Labelled Comp Radiopharm. 2015 Apr;58(4):156-62. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6813 mL | 18.4067 mL | 36.8134 mL | 92.0336 mL |
| 5 mM | 0.7363 mL | 3.6813 mL | 7.3627 mL | 18.4067 mL | |
| 10 mM | 0.3681 mL | 1.8407 mL | 3.6813 mL | 9.2034 mL | |
| 15 mM | 0.2454 mL | 1.2271 mL | 2.4542 mL | 6.1356 mL | |
| 20 mM | 0.1841 mL | 0.9203 mL | 1.8407 mL | 4.6017 mL | |
| 25 mM | 0.1473 mL | 0.7363 mL | 1.4725 mL | 3.6813 mL | |
| 30 mM | 0.1227 mL | 0.6136 mL | 1.2271 mL | 3.0678 mL | |
| 40 mM | 0.0920 mL | 0.4602 mL | 0.9203 mL | 2.3008 mL | |
| 50 mM | 0.0736 mL | 0.3681 mL | 0.7363 mL | 1.8407 mL | |
| 60 mM | 0.0614 mL | 0.3068 mL | 0.6136 mL | 1.5339 mL | |
| 80 mM | 0.0460 mL | 0.2301 mL | 0.4602 mL | 1.1504 mL | |
| 100 mM | 0.0368 mL | 0.1841 mL | 0.3681 mL | 0.9203 mL |
IDO5L Related Classifications
HY-15683 Related Classifications
Powered by Bioz